GENSCRIPT BIO (01548): Legend Biotech to Present Latest Data at ASH Annual Meeting

Stock News

Nov 04

GENSCRIPT BIO (01548) announced that Legend Biotech Corporation (an associate company of GENSCRIPT BIO, whose shares are listed on the NASDAQ Global Select Market in the form of American Depositary Shares) filed a Form 6-K with the U.S. Securities and Exchange Commission on November 3, 2025 (New York time) (before Hong Kong trading hours on November 4, 2025). The company disclosed plans to present the latest data related to CARVYKTI® and other pipeline candidates at the 67th American Society of Hematology (ASH) Annual Meeting, scheduled for December 6-9, 2025, in San Diego.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1110246984"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1110246984\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1110246984?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 07:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1110246984","market":"sh","top_or_hot":-1,"title":"GENSCRIPT BIO (01548): Legend Biotech to Present Latest Data at ASH Annual Meeting","media":"Stock News","content":"<p>GENSCRIPT BIO (01548) announced that Legend Biotech Corporation (an associate company of GENSCRIPT BIO, whose shares are listed on the NASDAQ Global Select Market in the form of American Depositary Shares) filed a Form 6-K with the U.S. Securities and Exchange Commission on November 3, 2025 (New York time) (before Hong Kong trading hours on November 4, 2025). The company disclosed plans to present the latest data related to CARVYKTI® and other pipeline candidates at the 67th American Society of Hematology (ASH) Annual Meeting, scheduled for December 6-9, 2025, in San Diego.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GENSCRIPT BIO (01548): Legend Biotech to Present Latest Data at ASH Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGENSCRIPT BIO (01548): Legend Biotech to Present Latest Data at ASH Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-04 07:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GENSCRIPT BIO (01548) announced that Legend Biotech Corporation (an associate company of GENSCRIPT BIO, whose shares are listed on the NASDAQ Global Select Market in the form of American Depositary Shares) filed a Form 6-K with the U.S. Securities and Exchange Commission on November 3, 2025 (New York time) (before Hong Kong trading hours on November 4, 2025). The company disclosed plans to present the latest data related to CARVYKTI® and other pipeline candidates at the 67th American Society of Hematology (ASH) Annual Meeting, scheduled for December 6-9, 2025, in San Diego.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000306685.HKD","symbol_name":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","start_time":0,"source_url":"","article_id":"1110246984","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1110246984","pubTimestamp":1762213449,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"GENSCRIPT BIO (01548) announced that Legend Biotech Corporation (an associate company of GENSCRIPT BIO, whose shares are listed on the NASDAQ Global Select Market in the form of American Depositary...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","BK1583":"高瓴概念","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","01548":"金斯瑞生物科技","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","BK1141":"生命科学工具和服务","BK1576":"医药外包概念"},"translate_title":"金斯瑞生物(01548)：传奇生物将在ASH年会上展示最新数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"GENSCRIPT BIO (01548) announced that Legend Biotech Corporation (an associate company of GENSCRIPT BIO, whose shares are listed on the NASDAQ Global Select Market in the form of American Depositary Shares) filed a Form 6-K with the U.S. Securities and Exchange Commission on November 3, 2025 (New York time) (before Hong Kong trading hours on November 4, 2025). The company disclosed plans to present the latest data related to CARVYKTI® and other pipeline candidates at the 67th American Society of Hematology (ASH) Annual Meeting, scheduled for December 6-9, 2025, in San Diego.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}